Skip to main content
logo
Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
12.86
-0.27 (-2.06%)
At close: Aug 24, 2026, 4:00 PM EDT
13.24
+0.38 (2.95%)
Pre-market: Aug 25, 2026, 8:24 AM EDT

Candel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.130.13
Revenue Growth
----0%0%
Cost of Revenue
----20.3514.59
Gross Profit
-----20.22-14.47
Selling, General & Admin
23.6318.4214.614.4114.511.26
Research & Development
48.3629.7618.7323.59--
Operating Expenses
71.9848.1833.333814.511.26
Operating Income
-71.98-48.18-33.33-38-34.72-25.73
Interest Expense
-4.72-2.12-2.09-2.6-1.71-0.05
Interest & Investment Income
5.053.921.092.081.22-
Other Non Operating Income (Expenses)
-16.888.29-20.80.9716.42-10.81
EBT Excluding Unusual Items
-88.52-38.09-55.14-37.55-18.79-36.59
Asset Writedown
-0.01-0.09-0.04-0.39--
Other Unusual Items
-----0.46
Pretax Income
-88.53-38.18-55.18-37.94-18.79-36.12
Net Income
-88.53-38.18-55.18-37.94-18.79-36.12
Net Income to Common
-88.53-38.18-55.18-37.94-18.79-36.12
Net Income Growth
------
Shares Outstanding (Basic)
625332292919
Shares Outstanding (Diluted)
625332292919
Shares Change
45.29%67.19%9.47%0.39%52.72%62.49%
EPS (Basic)
-1.44-0.72-1.74-1.31-0.65-1.91
EPS (Diluted)
-1.44-0.72-1.74-1.31-0.65-1.91
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-57.32-38.9-27.04-34.7-32.72-24.05
Free Cash Flow Per Share
-0.93-0.73-0.85-1.20-1.14-1.27
Operating Margin
-----27777.60%-20580.80%
Profit Margin
-----15035.20%-28899.20%
Free Cash Flow Margin
-----26172.80%-19242.40%
EBITDA
-71.3-47.33-32.34-37.04-33.94-25.49
D&A For EBITDA
0.680.850.990.960.780.23
EBIT
-71.98-48.18-33.33-38-34.72-25.73
SEC Filings: 10-K · 10-Q